The Flu Shot Drama at the FDA - The Journal Recap
Podcast: The Journal
Published: 2026-02-18
Duration: 20 minutes
Guests: Liz Essley Whyte
Summary
The FDA's decision to review Moderna's new flu shot marks a shift in regulatory dynamics, highlighting internal tensions and evolving vaccine approval processes.
What Happened
The FDA's initial refusal to review Moderna's application for a new flu shot surprised many, given the agency had previously agreed on the study's methodology. This decision was part of a series of regulatory reversals that have characterized the FDA's recent approach. Moderna, known for its mRNA COVID vaccine, aims to apply similar technology to flu shots, promising a quicker response to seasonal flu variations.
The mRNA flu vaccine could revolutionize flu prevention by allowing faster adaptation to emerging strains, unlike the traditional method that relies on predicting dominant strains. Despite the potential, the FDA demanded a higher standard of evidence, requiring randomized controlled trials, which are more costly and time-consuming.
Dr. Vinay Prasad, a controversial figure at the FDA, played a central role in the initial rejection of Moderna's application, citing inadequate comparative trials. Prasad's stance reflects a broader skepticism within the Trump administration-aligned FDA leadership towards mRNA vaccines.
Prasad's tenure has been marked by controversy, including disputes with FDA staff and criticism for his remote work arrangements. His approach has raised concerns among pharmaceutical companies about the FDA's unpredictability in drug approvals.
The FDA's change of heart, influenced by discussions with the White House and Health and Human Services, could see Moderna's flu vaccine available by the 2026-2027 flu season. This decision underscores the FDA's internal conflicts and the balancing act between regulatory rigor and innovation.
The uncertainty at the FDA, with frequent leadership changes and varying regulatory standards, has left pharmaceutical companies wary. While some welcome the Trump administration's reforms, others are concerned about the impact on drug development and approval timelines.
Key Insights
- Moderna's attempt to create an mRNA-based flu vaccine faces an unexpected hold-up from the FDA, despite the agency's prior agreement on the study methodology. The demand for randomized controlled trials, while ensuring efficacy, adds significant time and cost barriers.
- The mRNA technology that Moderna aims to use for flu vaccines could vastly improve response times to new flu strains, unlike traditional methods that rely on early predictions of dominant strains. This shift could potentially reduce the annual mismatch risk seen with conventional flu vaccines.
- Dr. Vinay Prasad's involvement in rejecting Moderna's application highlights internal disagreements within the FDA, especially around the Trump-era skepticism of mRNA vaccines. His controversial stance on comparative trials mirrors broader regulatory shifts that have left pharmaceutical companies uneasy.
- The FDA's eventual reconsideration of Moderna's application, influenced by discussions with the White House, points to an ongoing struggle within the agency to balance regulatory stringency with the need for innovation. This internal conflict could push the availability of Moderna's flu vaccine to the 2026-2027 season.
Key Questions Answered
Why did the FDA initially refuse to review Moderna's flu shot application?
The FDA refused to review Moderna's application because it deemed the clinical trials inadequate, particularly lacking a proper comparative analysis with a higher-dose flu vaccine.
Who is Dr. Vinay Prasad and what role does he play at the FDA?
Dr. Vinay Prasad is the head of vaccines at the FDA, known for his critical stance on mRNA vaccines and his controversial decisions, including blocking Moderna's flu shot application.
How does mRNA technology differ from traditional vaccines?
mRNA vaccines teach the body to produce a protein that triggers an immune response, offering quicker adaptation to virus variants compared to traditional vaccines that use weakened forms of the virus.